Dermal fibroblasts genetically modified to express Runx2/Cbfa1 as a mineralizing cell source for bone tissue...

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Cell Biology

Background:

• Cell-based bone tissue engineering requires a reliable source of mineralizing cells.
• Dermal fibroblasts are an accessible cell type with high expansion capacity.
• Current strategies face limitations in generating sufficient osteogenic cells.

Purpose of the Study:

• To investigate the use of Runx2 (Runt-related transcription factor 2) gene delivery to induce osteogenesis in dermal fibroblasts.
• To evaluate the potential of engineered fibroblasts as a cell source for bone regeneration.

Main Methods:

• Retroviral gene delivery of Runx2 into primary dermal fibroblasts.
• Culture of engineered fibroblasts on 3D collagen scaffolds.
• Analysis of osteogenic gene expression and mineral deposition in vitro.
• In vivo implantation in a subcutaneous site to assess mineralization.

Main Results:

• Runx2 overexpression induced osteogenic gene expression and mineralized nodule formation in vitro.
• Fourier transform infrared analysis confirmed hydroxyapatite deposition by engineered cells.
• Runx2-transduced fibroblasts formed mineralized templates in vivo.
• Immunohistochemistry showed co-localization of engineered cells with mineral deposits.

Conclusions:

• Runx2 genetic engineering effectively converts dermal fibroblasts into a mineralizing cell source.
• This strategy holds promise for bone repair applications, especially in patients with impaired endogenous osteoprogenitor recruitment.
• Engineered fibroblasts offer a viable cellular therapy for skeletal regeneration.